Merck Sharp & Dohme Corp. - Recruiting 18 years or older. - A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients With Complicated Urinary Tract Infection (cUTI).
MK-7655 250 mg with imipenem/cilastatin; MK-7655 125 mg with imipenem/cilastatin; imipenem/cilastatin 500 mg; Placebo to MK-7655
AstraZeneca - Recruiting 18 years to 90 years. - An Open-Label, Randomized, Multicenter, Phase III Study of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant Gram Negative Pathogens.
Ceftazidime - Avibactam ( CAZ-AVI); Best Available Therapy; Metronidazole
University Hospital Inselspital, Berne - Recruiting 18 years to 70 years. - Symptomatic Therapy of Uncomplicated Lower Urinary Tract Infections in the Ambulatory Setting. A Randomized, Double Blind Trial.
Study Group for Urogenital Diseases, Italy - Recruiting 18 years to 75 years. - INTRAVESICAL ADMINISTRATION OF COMBINED HYALURONIC ACID (HA) AND CHONDROITIN SULPHATE (CS) vs. STANDARD OF CARE FOR THE TREATMENT OF RECURRENT URINARY TRACT INFECTIONS (RUTIs).
Swiss Paraplegic Centre Nottwil - Recruiting 18 years to 90 years. - Clinical Value of Homeopathic Assessment and Treatment for Prophylaxis of Recurrent Urinary Tract Infections in Persons With Spinal Cord Injury.
individual homeopathic treatment; standard treatment without homeopathy
AstraZeneca - Recruiting 18 years to 90 years. - A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, With a Gram Negative Pathogen in Hospitalized Adults.
CAZ-AVI; Doripenem; Either switch to oral therapy: 500 mg of Ciprofloxacin (oral); or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
MeMed Diagnostics Ltd. - Recruiting 1 Month to 18 years. - A Retrospective, Blinded Validation Study to Assess the Accuracy of a Host-response Based Diagnostics for Distinguishing Between Bacterial and Viral Etiologies in Pediatric Patients With an Acute Febrile Disease.
University Hospital, Akershus - Recruiting 18 years to 70 years. - Probiotics/Lactobacillus as a Prophylactic Aid in Recurrent Bacterial Cystitis in Women. A Randomized, Prospective, Double-Blinded, Placebo Controlled, Multi-Center Study..
University of Siena - Recruiting 16 years or older. - Infections Caused by Enterobacteriaceae Producing Extended-Spectrum á-Lactamases in Italy: Molecular Epidemiology, Clinical Impact, Treatment Outcome and Risk Factors.
Risk factors for infections due to ESBL+ Enterobacteriaceae; Risk factors for inadequate initial antimicrobial therapy; Overall and 30-day mortality in bad first antibiotic therapy